Sino Biopharm

News

Pinky promise made by stone statue hands

Alnylam bets on Tenaya RNAi tech, and other licensing news

This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A Pharma.

News

MSD, AZ partner LaNova bought by Sino Biopharm for $951m

LaNova Medicines is being bought out by minority shareholder Sino Biopharm in a deal valued at around $951 million.

Patients

pharmaphorum podcast Episode 254, Thomas Goetz, Drug Story

Every drug is a story, with Thomas Goetz

Thomas Goetz, creator and host of the Drug Story podcast on recognising pharmaceutical medicine as the socially and morally complex market that it is.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks